Now, AstraZeneca has announced its intentions to invest $100m in a research facility in China, focusing on the relationship between cancer and genetics in Chinese patients. The centre, which is likely to be built in Shanghai in 2009, will also be used to create links with academic research centres in China.
Other pharma companies which have already set up research facilities in China include Novo Nordisk, Eli Lilly and Pfizer. The trend in China has been matched by similar developments in India, where both AstraZeneca and GlaxoSmithKline have research connections.
The question of which country is the best one to invest in – China or India – is being hotly debated in the pharmaceutical sector.
AZ to invest $100m in Chinese Research
Financial Times, May 27/May 28 2006
Review by Morice Mendoza